LTKfarma Pursues Development Of Proprietary TK Therapy

Published: Jan 08, 2010

Evry, France – January 8, 2010 LTKfarma announces that in the patent litigation initiated against Molmed S.p.A. by Université Pierre et Marie Curie (UPMC) and LTKfarma on June 8, 2007, and based on the Italian part of European patent EP 0 564 646, the Court of Milan ruled on October 21, 2009, that the plaintiffs had the standing to bring the suit. Because of lack of sufficient evidence of an imminent marketing of the TK therapy by Molmed, the Court rejected UPMC and LTKfarma’s claims.

Nevertheless, considering the claims of UPMC and LTKfarma legitimate in substance, the Court rejected Molmed’s counterclaim for awarding “punitive” damages.

In conclusion, the Italian part of European patent EP 0 564 646 remains in force.

UPMC and LTKfarma will pursue their efforts for a proper respect of their rights on proprietary TK therapy.

About LTKfarma

LTKfarma is a biotechnology company founded in 2006 and located at the Genopole of Evry (France). The company is based on 20 years of research in immunology and on the clinical use of suicide genes, notably the thymidine kinase gene (TK). The company is dedicated to the development of new cell therapies products to improve allogeneic hematopoietic cells transplantation by providing, through TK Therapy, a mean of controlling Graft vs Host Disease (GvHD), a severe immune reaction that occurs following transplantation. The TK therapy has been validated in several clinical trials. Allogeneic hematopoietic cell transplantation is currently used to treat various blood cancers after relapse following standard chemotherapy. The security given by LTK products will allow to improve the current performances of the procedure and to extend its usage not only in the treatment of blood cancer, but also in other pathologies such as severe forms of auto-immune diseases or solid tumors.

For more information please go to:

Back to news